ClinicalTrials.gg
CompletedNCT01895218PP-01Updated Apr 29, 2015

Treatment of Women After Postpartum Haemorrhage

A Phase 3 interventional study of Iron isomaltoside 1000 and Standard medical Care in Postpartum Haemorrhage, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-29.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary purpose of this study is to compare the efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.

02

Conditions studied

  • Postpartum Haemorrhage

Browse trials for

03

In context

Postpartum Hemorrhage

469 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.

This study's enrollment of 200 is above the median of 148 across 360 interventional studies indexed under Postpartum Hemorrhage.

Browse Postpartum Hemorrhage studies →

Lead sponsor

Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with PPH ≥ 700 and ≤ 1000 mL or PPH > 1000 mL and > 6.5 g/dL (4.0 mmol/L) measured > 12 hours after delivery
  2. Willingness to participate and signed the form

Exclusion criteria

Exclusion Criteria:

  1. Women aged \< 18 years
  2. Multiple births
  3. Peripartum RBC transfusion
  4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  5. Known to parenteral iron or any in the drug products
  6. Women with a history of active asthma within the last 5 years or a history of multiple allergies
  7. Known decompensated liver cirrhosis and active hepatitis
  8. Women with HELLP (Haemolysis Elevated Liver enzymes Low count) syndrome (defined according to "Dansk Selskab for Obstetrik og Gynækologi guidelines")
  9. Active acute infection assessed by clinical judgement
  10. Rheumatoid arthritis with symptoms or signs of active joint inflammation
  11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)
  12. Not able to read, speak and understand the Danish language
  13. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline
  14. Any other medical condition that, in the opinion of the Investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. For example, a , uncontrolled hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside 1000 (Monofer®)

    Drug: Iron isomaltoside 1000

  • Active comparator
    Standard medical Care

    Other: Standard medical Care

Interventions

  • A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.

    Also known as: Monofer®

  • OtherStandard medical Care

    Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day

06

What researchers measure

Primary outcomes

  1. Physical fatigue

    The primary objective of this study is to compare efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.

    Time frame: From exposure to 12 weeks post-exposure

Secondary outcomes

  1. Change in Hb concentration

    Time frame: From exposure to week 1, 3, 8 and 12 post-exposure

  2. Change in concentrations of p-ferritin

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  3. Change in Fatigue symptoms

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  4. Change in postpartum depression symptoms

    Time frame: From exposure to 12 weeks post-exposure

  5. Breastfeeding

    Time frame: From exposure to 12 weeks post-exposure

  6. RCB transfusions

    Time frame: From exposure to 12 weeks post-exposure

  7. Adverse drug reactions (ADRs)

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  8. Change in concentrations of p-iron

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  9. Change in concentrations of p-transferrin

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  10. Change in concentrations of transferrin saturation (TSAT)

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  11. Change in concentrations of reticulocyte count

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  12. Change in concentrations of mean reticulocyte haemoglobin content (CHr)

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  13. Change in haematology parameters

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

Other outcomes

  1. Change in anaemia symptoms

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

  2. Change in gastrointestinal symptoms

    Time frame: From exposure to day 3, week 1, 3, 8 and 12 post-exposure

07

Study locations

1 site
  • Copenhagen, Denmark
08

References and documents

Publications

  • Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med. 2019 Sep;32(17):2797-2804. doi: 10.1080/14767058.2018.1449205. Epub 2018 Mar 20. PubMed 29558233 ↗
  • Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial. Trials. 2015 Jan 14;16:5. doi: 10.1186/1745-6215-16-5. PubMed 25588587 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 10, 2013
Start
Jun 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Apr 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01895218
Lead sponsor
Pharmacosmos A/S
Collaborators
BioStata
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jun 2013
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Apr 29, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion